# Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas

> **NCT01595321** · PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 19 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Cyclophosphamide
- **BIOLOGICAL:** GVAX Pancreas Vaccine
- **RADIATION:** Stereotactic Body Radiation
- **DRUG:** FOLFIRINOX

## Key facts

- **NCT ID:** NCT01595321
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10-29
- **Primary completion:** 2023-10-18
- **Final completion:** 2023-10-18
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2024-08-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01595321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01595321, "Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01595321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*